Ionis Pharmaceuticals Inc (NASDAQ: IONS) is -9.15% lower on its value in year-to-date trading and has touched a low of $30.23 and a high of $52.34 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IONS stock was last observed hovering at around $31.85 in the last trading session, with the day’s loss setting it -0.09%.
Currently trading at $31.76, the stock is -0.54% and -5.67% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.46 million and changing -0.28% at the moment leaves the stock -20.48% off its SMA200. IONS registered -29.98% loss for a year compared to 6-month loss of -32.31%.
The stock witnessed a -6.73% gain in the last 1 month and extending the period to 3 months gives it a -6.42%, and is -0.16% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.30% over the week and 4.34% over the month.
Ionis Pharmaceuticals Inc (IONS) has around 1069 employees, a market worth around $5.05B and $705.56M in sales. Profit margin for the company is -64.28%. Distance from 52-week low is 5.06% and -39.32% from its 52-week high. The company has generated returns on investments over the last 12 months (-17.87%).
with sales reaching $125.5M over the same period.The EPS is expected to shrink by -27.32% this year, but quarterly earnings will post -5.77% year-over-year. Quarterly sales are estimated to grow 5.46% in year-over-year returns.
The shares outstanding are 157.91M, and float is at 154.56M with Short Float at 7.84%.
The top institutional shareholder in the company is FMR LLC with over 21.89 million shares valued at $$1.04 billion. The investor’s holdings represent 15.044 of the IONS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.85 million shares valued at $$659.89 million to account for 9.5135 of the shares outstanding. The other top investors are T. ROWE PRICE INVESTMENT MANAGEMENT, INC. which holds 12.64 million shares representing 8.6598 and valued at over $$602.41 million, while BLACKROCK INC. holds 7.0916 of the shares totaling 10.32 million with a market value of $$491.9 million.
Ionis Pharmaceuticals Inc (IONS) Insider Activity
The most recent transaction is an insider sale by O’NEIL PATRICK R., the company’s EVP CLO & General Counsel. SEC filings show that O’NEIL PATRICK R. sold 1,207 shares of the company’s common stock on Feb 20 ’25 at a price of $32.35 per share for a total of $39046.0. Following the sale, the insider now owns 56245.0 shares.
Ionis Pharmaceuticals Inc disclosed in a document filed with the SEC on Feb 04 ’25 that O’NEIL PATRICK R. (EVP CLO & General Counsel) sold a total of 6,165 shares of the company’s common stock. The trade occurred on Feb 04 ’25 and was made at $31.62 per share for $0.19 million. Following the transaction, the insider now directly holds 57452.0 shares of the IONS stock.
Still, SEC filings show that on Feb 04 ’25, Monia Brett P (Chief Executive Officer) disposed off 38,843 shares at an average price of $31.65 for $1.23 million. The insider now directly holds 180,683 shares of Ionis Pharmaceuticals Inc (IONS).
